{"entity":{"id":"instil-bio","kind":"company","name":"Instil Bio","aka":["Axion Bio"],"tldr":"Instil Bio is a listed biotechnology company that previously developed immune cell therapies and then a two-target antibody for solid tumours. It stopped that antibody programme in January 2026 and now seeks new medicines to acquire or license.","summary":"Instil Bio, Inc. is headquartered in Dallas, Texas, was incorporated in Delaware in August 2018 and began operations in 2019; its shares trade on Nasdaq as TIL. It previously developed tumour-infiltrating lymphocyte cell therapies, including a folate receptor alpha CoStAR TIL programme (ITIL-168 and ITIL-306), which it discontinued. In August 2024 its wholly owned subsidiary Axion Bio, Inc. in-licensed AXN-2510, a PD-L1 and VEGF bispecific antibody, from ImmuneOnco Biopharmaceuticals (Shanghai); the phase 1 trial NCT07159828 in advanced solid tumours was terminated, and the licence ended in January 2026. Its stated strategy is to pursue acquisitions or in-licensing of therapeutic candidates. Its first cancer trial registered under the sponsor name Axion Bio, Inc, NCT07159828, was posted on ClinicalTrials.gov in September 2025.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://instilbio.com/"},{"label":"Instil Bio Form 10-K for 2025 (SEC)","url":"https://www.sec.gov/Archives/edgar/data/1789769/000178976926000019/til-20251231.htm"},{"label":"ClinicalTrials.gov: phase 1 trial of AXN-2510 (NCT07159828)","url":"https://clinicaltrials.gov/study/NCT07159828"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy","cell-therapy"],"technologies":["bispecific-antibody","til-therapy"],"targets":["pdl1","vegf"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Facts come from the Form 10-K filed on 27 March 2026, read on 29 October 2026; the company website gives little detail and the investor site refused an automated fetch.","The reason for discontinuing AXN-2510 is not stated in the part of the filing read.","Instil Bio's own TIL trials predate 2024; only the Axion Bio sponsor name first appears on the registry in 2025."],"hq":"Dallas, TX","country":"US","companyType":"biotech","website":"https://instilbio.com/","ticker":"TIL","stage":"public","investors":[],"funding":[]},"route":"/companies/instil-bio/","neighbours":{"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"til-therapy","kind":"technology","name":"TIL therapy","route":"/technologies/til-therapy/"}],"target":[{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"},{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/"}]}}